Science丨曹雪涛组阐述病毒感染调控的新机制

2017-10-28 BioArt BioArt

日前,Science杂志在线刊登了第二军医大学医学免疫学国家重点实验室、中国工程院院士曹雪涛研究团队题为“An Interferon-independent lncRNA promotes viral replication by modulating cellular metabolism”的研究论文,报道了非编码RNA lncRNA-ACOD1通过结合细胞内代谢酶GOT2调控胞内代谢促进病毒逃

日前,Science杂志在线刊登了第二军医大学医学免疫学国家重点实验室、中国工程院院士曹雪涛研究团队题为“An Interferon-independent lncRNA promotes viral replication by modulating cellular metabolism”的研究论文,报道了非编码RNA lncRNA-ACOD1通过结合细胞内代谢酶GOT2调控胞内代谢促进病毒逃逸的新发现。该发现为病毒感染调控机制提出了新观点,也为有效防治病毒感染性疾病提供了新思路和潜在药物研发靶标。

病毒感染调控一直以来是免疫学研究的热点。干扰素是机体抵抗病毒感染的关键性细胞因子,通过激活一系列干扰素诱导性基因的表达,从而激活机体的抗病毒能力。然而,干扰素以外的调控机制,尤其是病毒如何调控宿主细胞代谢的,目前知之甚少。

在国家自然科学基金委、中国医学科学院创新基金等资助下,医学免疫学国家重点实验室主任曹雪涛院士、王品副教授与浙江大学医学院免疫学研究所博士生徐俊芳等,从基因组中表达量很高但却功能未知的非编码RNA入手,筛选到其中一个lncRNA—lncRNA-ACOD1,在体内外均能显着的促进多种病毒的复制。深入研究发现lncRNA-ACOD1通过不依赖干扰素的一条新作用模式促进病毒感染,表达谱检测显示代谢通路受到lncRNA-ACOD1的明显调控。分子机制上,lncRNA-ACOD1在细胞浆中结合代谢中重要的氨基转移酶GOT2,在分子构象上靠近酶底物结合位点,有利于其催化反应。体外酶活性实验和体内LC-MS质谱代谢物检测证实lncRNA-ACOD1能够促进GOT2的代谢活性,且GOT2缺失则lncRNA-ACOD1促进病毒复制的功能丧失,补充GOT2或其催化底物能够逆转lncRNA-ACOD1缺失造成的病毒复制减弱。这证实lncRNA-ACOD1通过促进GOT3酶活性影响代谢,促进了病毒复制的作用模式。

该研究揭示了病毒感染通过lncRNA调控细胞代谢的新机制,解释了病毒调控代谢的分子机制,为临床上研发新的抗病毒药物提供了潜在的研究靶标。同时进一步完善了病毒感染调控网络,提出了干扰素之外的病毒感染调控新通路,将非编RNA、代谢调控和病毒感染三者联系在了一起,为免疫调控机制的研究提供了新的思路。

值得一提的是,该工作为曹雪涛课题组在LncRNA领域发表的第二篇Science论文,而且两篇论文的第一作者均为王品博士。王品博士现为海军军医大学(第二军医大学)免疫学研究所暨医学免疫学国家重点实验室副教授,国家优青。

原始出处:
Pin Wang, Junfang Xu, Yujia Wang, et al.An interferon-independent lncRNA promotes viral replication by modulating cellular metabolism.Science. 26 Oct 2017:DOI: 10.1126/science.aao0409

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1351465, encodeId=cc811351465eb, content=<a href='/topic/show?id=c6e06030207' target=_blank style='color:#2F92EE;'>#曹雪涛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60302, encryptionId=c6e06030207, topicName=曹雪涛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Oct 30 04:45:00 CST 2017, time=2017-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375715, encodeId=f0c813e571531, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Mon Oct 30 04:45:00 CST 2017, time=2017-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256798, encodeId=dbf3256e986e, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Oct 29 00:25:41 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256714, encodeId=5205256e1424, content=学习了新知识学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sat Oct 28 17:03:58 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256688, encodeId=e555256688e0, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Oct 28 14:54:21 CST 2017, time=2017-10-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1351465, encodeId=cc811351465eb, content=<a href='/topic/show?id=c6e06030207' target=_blank style='color:#2F92EE;'>#曹雪涛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60302, encryptionId=c6e06030207, topicName=曹雪涛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Oct 30 04:45:00 CST 2017, time=2017-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375715, encodeId=f0c813e571531, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Mon Oct 30 04:45:00 CST 2017, time=2017-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256798, encodeId=dbf3256e986e, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Oct 29 00:25:41 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256714, encodeId=5205256e1424, content=学习了新知识学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sat Oct 28 17:03:58 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256688, encodeId=e555256688e0, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Oct 28 14:54:21 CST 2017, time=2017-10-28, status=1, ipAttribution=)]
    2017-10-30 jichang
  3. [GetPortalCommentsPageByObjectIdResponse(id=1351465, encodeId=cc811351465eb, content=<a href='/topic/show?id=c6e06030207' target=_blank style='color:#2F92EE;'>#曹雪涛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60302, encryptionId=c6e06030207, topicName=曹雪涛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Oct 30 04:45:00 CST 2017, time=2017-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375715, encodeId=f0c813e571531, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Mon Oct 30 04:45:00 CST 2017, time=2017-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256798, encodeId=dbf3256e986e, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Oct 29 00:25:41 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256714, encodeId=5205256e1424, content=学习了新知识学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sat Oct 28 17:03:58 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256688, encodeId=e555256688e0, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Oct 28 14:54:21 CST 2017, time=2017-10-28, status=1, ipAttribution=)]
    2017-10-29 Y—xianghai

    学习了新知识

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1351465, encodeId=cc811351465eb, content=<a href='/topic/show?id=c6e06030207' target=_blank style='color:#2F92EE;'>#曹雪涛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60302, encryptionId=c6e06030207, topicName=曹雪涛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Oct 30 04:45:00 CST 2017, time=2017-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375715, encodeId=f0c813e571531, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Mon Oct 30 04:45:00 CST 2017, time=2017-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256798, encodeId=dbf3256e986e, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Oct 29 00:25:41 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256714, encodeId=5205256e1424, content=学习了新知识学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sat Oct 28 17:03:58 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256688, encodeId=e555256688e0, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Oct 28 14:54:21 CST 2017, time=2017-10-28, status=1, ipAttribution=)]
    2017-10-28 Y—xianghai

    学习了新知识学习了新知识

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1351465, encodeId=cc811351465eb, content=<a href='/topic/show?id=c6e06030207' target=_blank style='color:#2F92EE;'>#曹雪涛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60302, encryptionId=c6e06030207, topicName=曹雪涛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Oct 30 04:45:00 CST 2017, time=2017-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375715, encodeId=f0c813e571531, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Mon Oct 30 04:45:00 CST 2017, time=2017-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256798, encodeId=dbf3256e986e, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Oct 29 00:25:41 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256714, encodeId=5205256e1424, content=学习了新知识学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sat Oct 28 17:03:58 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256688, encodeId=e555256688e0, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Oct 28 14:54:21 CST 2017, time=2017-10-28, status=1, ipAttribution=)]
    2017-10-28 1e0f8808m18(暂无匿称)

    学习了.谢谢分享.

    0

相关资讯

Immunity:中国科学家攻克寨卡病毒难题,首次在猴体发现抑制病毒感染的小分子

对于寨卡病毒感染,目前仍然没有能够效防治的疫苗或药物。今日,Immunity在线发表了一项我国科学家在抗寨卡病毒研究领域取得的重大进展。研究表明,天然免疫小分子化合物25-羟基胆固醇对寨卡病毒感染所致疾病具有明确的保护效果。生物探索第一时间采访了该研究的共同第一作者李春峰博士。

Cell Immunity: 炎症小体的激活降低了机体抗DNA病毒感染的能力

炎症小体的激活降低了机体抗DNA病毒感染的能力

Nat Commun:登革热感染究竟会不会增强寨卡病毒的发病?

这项研究的结果显示,与之前没有感染过黄热病毒的猕猴相比,感染过登革热病毒的猕猴能够更快的清除血液中寨卡病毒的数量,暗示曾经登革热病毒的感染可能导致免疫反应的变化缩短清除病毒的时间,但是并不会导致寨卡病毒的发病机制的增强。但是值得注意的是,这项研究的结果与今年稍早时间的一项报导的结果存在争议。在另一项研究中,登革热的感染所产生的抗体会促进寨卡病毒的发病机制(请参考梅斯医学的之前报导)。

Nature Immunology:microRNA有望加入anti-PD-1疗法,提高T细胞活性

研究人员还发现miR-31丢失的老鼠在感染LCMV后, 体内CD8+T细胞的抑制受体比如PD-1的表达量都下降。CD8+T细胞的数量及针对LCMV的特异性CD8+T细胞也得到富集。这一结果暗示,未来有可能针对miR-31,通过抑制其功能达到抑制PD-1信号的作用,从而产生更多的针对肿瘤细胞特定的CD8+T细胞,改善免疫治疗的疗效。这一研究证明了miR-31为T细胞耗竭的重要调节因子。

如何区分细菌感染与病毒感染?

细菌感染和病毒感染的临床本质和治疗方法都不同,因此对于怀疑感染的患者首先要做的就是鉴别感染的病原体。但如何鉴别这一问题其实至今都尚无定论,那么是否存在准确且敏感的标志物?如何快速、简便地鉴别细菌感染与病毒感染呢?

Nat Microbiol:科学家有望开发新型疫苗和抗病毒药物

日前,一项刊登在国际杂志Nature Microbiology上的研究报告中,来自Sanford Burnham Prebys医学发现研究所的研究人员通过研究鉴别出了一种机体先天性免疫应答的新型调节子,这种先天性免疫反应也就是机体应对外来入侵者出现的快速天然免疫反应,相关研究或为研究人员开发新